June is Vitiligo Awareness Month, and June 25 is World Vitiligo Day, but for an estimated 70 million people around the globe, this relatively common disorder is an everyday fact of life. An autoimmune condition characterized by the loss of skin color due to the destruction of pigment-producing melanocytes, vitiligo causes light patches of skin that can appear anywhere on the body and may spread over time. While it affects all racial groups equally, the visibility and impact of vitiligo tend to be more pronounced in people with darker skin tones due to the high contrast between depigmented patches and the surrounding skin.
That heightened contrast means that vitiligo is more than a cosmetic issue. It is one of the most emotionally and therapeutically challenging conditions in dermatology because depigmented areas can be difficult to conceal, making the condition highly visible and deeply personal. As a result, treatment often requires a carefully tailored approach, with clinicians focused on improving both clinical outcomes and patient quality of life.
Unique Challenges
“Vitiligo is not a cosmetic disease,” says Jessica Shiu, MD, PhD, assistant professor of dermatology at the University of California, Irvine. “It is associated with significant depression, stigmatization, and low self-esteem. I have patients who say that vitiligo has affected their marriage…. In certain cultures, it also affects their job prospects.”
The psychological burden of vitiligo can be profound, with patients reporting increased rates of anxiety, depression, eating disorders, and PTSD, particularly among those with darker skin tones. A recent social media-based international survey published in the Australasian Journal of Dermatology associated vitiligo with substantial psychosocial challenges, including stigma, behavioral adaptations, and limitations in daily activities. Investigators suggested that the impact of vitiligo extends well beyond visible depigmented lesions. Successful outcomes in patients with skin of color, they concluded, should address quality of life and psychological well-being as part of comprehensive clinical management.
Psychosocial Burden: Patients with darker skin tones may experience higher rates of anxiety, depression, eating disorders, and PTSD related to the visibility of the condition.
Cultural Stigma: Distress surrounding vitiligo can be exacerbated by misconceptions about contagion, leprosy, or divine punishment.
Treatment Access Barriers: Effective treatments, including narrowband UVB phototherapy, often require frequent clinic visits, making care costly or logistically difficult.
Historical Depigmentation Risks: Certain treatments, such as the topical depigmenting agent monobenzone, may worsen cosmetic outcomes in patients with darker skin tones.
For patients with darker skin tones, underrepresentation in clinical trials can make identifying safe and effective treatment options more challenging. Only 25% of U.S. vitiligo trials include non-White participants, limiting the data available for patients with skin of color. This highlights the importance of diversity in clinical research and equitable representation in future studies.
Tailoring Treatment
Treating vitiligo is also complicated because its exact cause is not fully understood. As an autoimmune disorder where the body’s immune system attacks its own pigment-producing cells, vitiligo is commonly treated with topical corticosteroids, light therapy, and, in some cases, surgical interventions such as skin grafting.
Vitiligo has two main subtypes: segmental vitiligo, which is typically unilateral and often presents in younger patients, and the more common nonsegmental form, which usually involves both sides of the body and may include multiple sites.
The level of disease activity often drives treatment decisions. For patients with nonsegmental vitiligo who show signs of active disease, the first goal is to stabilize disease progression and prevent further pigment loss.
“This is key because losing pigment can occur very quickly, but gaining pigment back is a very slow process,” said Dr. Shiu.
Stabilization typically involves suppressing immune responses with topical corticosteroids, topical calcineurin inhibitors, or a JAK inhibitor such as 1.5% ruxolitinib cream. Emerging systemic therapies, including JAK inhibitors such as ritlecitinib, upadacitinib, baricitinib, and povorcitinib, are also showing promising results in clinical trials. Because vitamin D deficiency can be common in African American patients, screening and supplementation may be beneficial. Adding phototherapy, which encourages melanocyte stem cells to migrate from hair follicles, can further improve outcomes, particularly when combined with topical or systemic therapies.
“There’s good data to show that combining topical treatment with phototherapy can augment the repigmentation that you see,” Dr. Shiu said. “So, if it’s possible, try to add phototherapy for your vitiligo patients, but sometimes, logistics for that are a challenge.”
Concluding Thoughts
Vitiligo highlights many of the dermatologic challenges that extend beyond clinical treatment, from the psychological burden associated with visible skin disease to the need for greater representation and inclusivity in clinical research. By maintaining a holistic view of patient needs, taking social and psychological factors into consideration, and tailoring treatment plans accordingly, clinicians can help improve both well-being and clinical outcomes during Vitiligo Awareness Month and throughout the year.
